TY  - JOUR 
AU  - Roe, M. T.
AU  - Li, Q. H.
AU  - Bhatt, D. L.
AU  - Bittner, V. A.
AU  - Diaz, R.
AU  - Goodman, S. G.
AU  - Harrington, R. A.
AU  - Jukema, J. W.
AU  - Lopez-Jaramillo, P.
AU  - Lopes, R. D.
AU  - Louie, M. J.
AU  - Moriarty, P. M.
AU  - Szarek, M.
AU  - Vogel, R.
AU  - White, H. D.
AU  - Zeiher, A. M.
AU  - Baccara-Dinet, M. T.
AU  - Steg, P. G.
AU  - Schwartz, G. G.
AU  - Iñiguez Romo, Andres
AU  - González Juanatey, José Ramón
AU  - González Juanatey, Carlos
PY  - 2019
SN  - 0009-7322
UR  - http://hdl.handle.net/20.500.11940/15734
AB  - BACKGROUND: The 2018 US cholesterol management guidelines recommend additional lipid-lowering therapies for secondary prevention in patients with low-density lipoprotein cholesterol >/=70 mg/dL or non-high-density lipoprotein cholesterol >/=100 mg/dL...
LA  - eng
KW  - Risk Factors
KW  - Dyslipidemias
KW  - Risk Assessment
KW  - Middle Aged
KW  - Humans
KW  - Antibodies
KW  - Treatment Outcome
KW  - Cholesterol
KW  - Time Factors
KW  - Recurrence
KW  - Acute Coronary Syndrome
KW  - Practice Guidelines as Topic
KW  - Anticholesteremic Agents
KW  - Aged
KW  - Serine Proteinase Inhibitors
KW  - Secondary Prevention
TI  - Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes
DO  - 10.1161/circulationaha.119.042551
T2  - Circulation
M2  - 1578
KW  - CHUS
KW  - CHUVI
KW  - HULA
VL  - 140
ER  -